Table 3.

Clinical demographics of patient groups from three NSCLC TMAs*

Brigham & Women's HospitalU.S. Biomax,§M.D. Anderson Cancer Center,§
AgeYears−0.02 (−0.03, 0.00)0.00 (−0.16, 0.02)−0.86 (−1.59, −0.12)
Gender Male (0)−0.14 (−0.50, 0.22)0.18 (−0.13, 0.49)−11.14 (−27.06, 4.78)
Female (1)
DifferentiationWell (1), moderate (2), poor (3)0.37 (0.12, 0.61)0.05 (−0.15, 0.24)−1.45 (−12.79, 9.88)
Tumor status (T)T1-4 (1-4)0.21 (0.04, 0.39)−6.43 (−16.64, 3.76)
Tumor sizecm0.20 (0.10, 0.30)−2.78 (−6.53, 0.97)
Nodal statusN0 (0), N1 (1), N2 (2)0.24 (−0.17, 0.64)−0.55 (−12.22, 11.13)
Pathologic stage**I-IV (1-4)−1.15 (−10.46, 8.16)
Smoking status††Never (0), former (1), current (2)0.13 (−0.12, 0.37)7.30 (−4.44, 19.03)
Tobacco story††Never (0), former, or current (1)0.29 (−0.22, 0.81)12.87 (−9.32, 35.06)
  • *Coefficient from linear regression, β (linear mixed models with patient ID; 95% confidence intervals). **P < 0.01

  • IHC was done using the 6.1B antibody.

  • Combined NSCLC patients.

  • §IHC was done using the 468642 antibody.

  • P < 0.05.

  • P < 0.001.

  • **Missing individual patient data from M.D. Anderson Cancer Center TMA.

  • ††Missing individual patient data from Brigham Women's & Hospital TMA.